Science· 2015Q1
The future of immune checkpoint therapy
- 4,832citations
- Q1SCImago
- 2015year
Short summary
Immune checkpoint therapy, which enhances T cell antitumor responses, has achieved durable cancer remissions in some patients, but understanding tumor microenvironment immune responses is key to expanding its benefits.
AI-generated from the title and abstract; the full text is not read.
Key points
- Immune checkpoint therapy enhances T cell antitumor immune responses.
- The therapy has led to durable clinical responses and long-term remissions in some cancer patients.
- Understanding immune responses in the tumor microenvironment is crucial for future advancements.
- Combination therapies targeting additional pathways are needed to benefit more patients.
AI-generated from the title and abstract; the full text is not read.
Abstract
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
The authors' abstract, as published at the source. Science, 2015 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Oncology
OncologyMedicine